Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 4/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257786 | 0.92 | MET (0.44) | TNK2METCCNCCDK8DDB1 | |
| SCHEMBL30546843 | 0.92 | MET (0.44) | TNK2METCCNCCDK8DDB1 | |
| SCHEMBL24257611 | 0.83 | IRAK4 (0.41) | FGFR1JAK3IRAK4JAK2 | |
| SCHEMBL24257712 | 0.80 | MEN1 (0.48) | TNK2METTTKL3MBTL1LMNA | |
| SCHEMBL30452371 | 0.80 | MEN1 (0.48) | TNK2METTTKL3MBTL1LMNA | |
| SCHEMBL24257696 | 0.76 | TNK2 (0.48) | TNK2METCCNCCDK8DDB1 | |
| SCHEMBL24257746 | 0.76 | ABL1 (0.40) | METFGFR1JAK3BTKIRAK4 | |
| SCHEMBL25282080 | 0.75 | MET (0.48) | TNK2METCCNCCDK8DDB1 | |
| SCHEMBL24257732 | 0.74 | CCNC (0.49) | TNK2METCCNCCDK8DDB1 | |
| SCHEMBL30452665 | 0.74 | CCNC (0.49) | TNK2METCCNCCDK8DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4196466-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | TNK2 968/4885MET 942/4885CCNC 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.